Called the TwoBIg technology, the technology allows to create bispecific antibodies in “super-CHO” cells. One of the two binding domains is directed towards FcgammaRIIIA sites.
BioJapan 2012, Chugai seminar on October 11, 2012
Chugai introduces novel platform technology to create antibodies for the treatment of autoimmune diseases